Evidence map›Paper›PMID 36503451›Full record

ReviewCurrent neuropharmacology2023

K

Aqeela Zahra, Ru Liu, Wenzhe Han, Hui Meng, Qun Wang, YunFu Wang, Susan L Campbell, Jianping Wu

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current neuropharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Application of Modulators of CaInternational journal of molecular sciences · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Aqeela ZahraSchool of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan 430070, China.
Ru LiuBeijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Wenzhe HanSchool of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan 430070, China.
Hui MengSchool of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan 430070, China.
Qun WangBeijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
YunFu WangTaihe Hospital, Hubei University of Medicine, Shiyan 442000, China.
Susan L CampbellAnimal and Poultry Sciences, Virginia Polytechnic Institute and State University, Blacksburg, VA, United States.
Jianping WuSchool of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan 430070, China.
Wuhan University of Technology · CNBeijing Tian Tan Hospital · CNCapital Medical University · CNHubei University of Medicine · CNUniversity of SialkotVirginia Tech · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although potassium channelopathies have been linked to a wide range of neurological conditions, the underlying pathogenic mechanism is not always clear, and a systematic summary of clinical manifestation is absent. Several neurological disorders have been associated with alterations of calcium-activated potassium channels (K

Indexed as

Nervous System DiseasesPotassium Channels, Calcium-ActivatedHumansPotassium Channels, Calcium-Activatedaction potentialchannelopathiesepilepsymodulatorspharmacologyPotassium channels

Identifiers

PMID36503451
PMCPMC10472807
OpenAlexW4311200317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.